Literature DB >> 11581424

Human immunodeficiency virus type 1 (HIV-1) non-B subtypes are similar to HIV-1 subtype B in that coreceptor specificity is a determinant of cytopathicity in human lymphoid tissue infected ex vivo.

N Malkevich1, C Womack, P Pandya, J C Grivel, A S Fauci, L Margolis.   

Abstract

We sought to determine the relationship between virus-mediated CD4(+) T-lymphocyte cytopathicity and viral coreceptor preference among various human immunodeficiency virus type 1 (HIV-1) subtypes in an ex vivo-infected human lymphoid tissue model. Our data show that all R5 HIV-1 infections resulted in mild depletion of CD4(+) T lymphocytes, whereas all X4 HIV-1 infections caused severe depletion of CD4(+) T lymphocytes regardless of their subtype origin. Thus, at least for the viruses within subtypes A, B, C, and E that were tested, coreceptor specificity is a critical factor that determines the ability of HIV-1 to deplete CD4(+) T cells in human lymphoid tissue infected ex vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11581424      PMCID: PMC114630          DOI: 10.1128/JVI.75.21.10520-10522.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo.

Authors:  S Glushakova; Y Yi; J C Grivel; A Singh; D Schols; E De Clercq; R G Collman; L Margolis
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

2.  Human immunodeficiency virus type 1 coreceptor preferences determine target T-cell depletion and cellular tropism in human lymphoid tissue.

Authors:  J C Grivel; M L Penn; D A Eckstein; B Schramm; R F Speck; N W Abbey; B Herndier; L Margolis; M A Goldsmith
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 induces apoptosis in CD4(+) but not in CD8(+) T cells in ex vivo-infected human lymphoid tissue.

Authors:  J C Grivel; N Malkevitch; L Margolis
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Infection of human tonsil histocultures: a model for HIV pathogenesis.

Authors:  S Glushakova; B Baibakov; L B Margolis; J Zimmerberg
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

5.  Increased CCR5 expression with decreased beta chemokine secretion in Ethiopians: relevance to AIDS in Africa.

Authors:  A Kalinkovich; Z Weisman; Q Leng; G Borkow; M Stein; Z Greenberg; S Zlotnikov; S Eitan; Z Bentwich
Journal:  J Hum Virol       Date:  1999 Sep-Oct

6.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

Authors:  G Scarlatti; E Tresoldi; A Björndal; R Fredriksson; C Colognesi; H K Deng; M S Malnati; A Plebani; A G Siccardi; D R Littman; E M Fenyö; P Lusso
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

7.  Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project.

Authors:  M Clerici; S Butto; M Lukwiya; M Saresella; S Declich; D Trabattoni; C Pastori; S Piconi; C Fracasso; M Fabiani; P Ferrante; G Rizzardini; L Lopalco
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

8.  Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

Authors:  M Koot; I P Keet; A H Vos; R E de Goede; M T Roos; R A Coutinho; F Miedema; P T Schellekens; M Tersmette
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

9.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  Change in coreceptor use correlates with disease progression in HIV-1--infected individuals.

Authors:  R I Connor; K E Sheridan; D Ceradini; S Choe; N R Landau
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

View more
  5 in total

1.  Inhibition of human immunodeficiency virus envelope glycoprotein- mediated single cell lysis by low-molecular-weight antagonists of viral entry.

Authors:  Navid Madani; Amy M Hubicki; Ana Luisa Perdigoto; Martin Springer; Joseph Sodroski
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

2.  A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.

Authors:  Christophe Vanpouille; Andrea Lisco; Marco Derudas; Elisa Saba; Jean-Charles Grivel; Beda Brichacek; Francesca Scrimieri; Raymond Schinazi; Dominique Schols; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

3.  Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.

Authors:  Jason A LaBonte; Navid Madani; Joseph Sodroski
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

4.  Replication and drug resistant mutation of HIV-1 subtype B' (Thailand B) variants isolated from HAART treatment individuals in China.

Authors:  Jianping Sun; Liying Ma; Xiaoling Yu; Yang Huang; Lin Yuan; Yiming Shao
Journal:  Virol J       Date:  2009-11-18       Impact factor: 4.099

5.  Exceptional molecular and coreceptor-requirement properties of molecular clones isolated from an Human Immunodeficiency Virus Type-1 subtype C infection.

Authors:  Prasanta K Dash; Nagadenahalli B Siddappa; Asokan Mangaiarkarasi; Aruna V Mahendarkar; Padmanabhan Roshan; Krishnamurthy Kumar Anand; Anita Mahadevan; Parthasarathy Satishchandra; Susarla K Shankar; Vinayaka R Prasad; Udaykumar Ranga
Journal:  Retrovirology       Date:  2008-03-07       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.